Navigation Links
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Date:11/15/2007

ng Board recommended that the trial be

stopped because it was not reaching its efficacy endpoints. GeoVax

responded to the discontinuance of Merck's trial by pointing out

significant differences between the GeoVax vaccine technology and the

technology used in the Merck trial.

GeoVax AIDS vaccines advancing in human trials represent a

significantly different vaccine approach, vaccine composition and

results to date than the Merck vaccine.

* Prototypes for the GeoVax vaccines were selected from a series of

trials in non-human primates for their ability to protect against

the development of AIDS when vaccinated individuals were

administered an AIDS causing virus. At each major step along the

development pathway, GeoVax vaccines providing the best protection

against AIDS were moved forward.

* GeoVax AIDS vaccines demonstrated excellent protective results in

non-human primate models, much better protective results than

reported for Merck's vaccine in similar models. GeoVax AIDS

vaccines protected 22/23 non-human primates for over 3 1/2 years

and 5/6 non-vaccinated controls died of AIDS post-AIDS virus

infection.

* GeoVax AIDS vaccines are designed to elicit protective antibodies

(Ab) as well as protective T cells (white blood cells) against the

AIDS virus. The Merck vaccine stimulates only T cells for providing

protection and does not include the Env protein of HIV which is the

target for protective antibody (Ab).

* Protective Ab has been difficult to elicit with HIV/AIDS vaccines.

GeoVax has approached this challenge by vaccinating with the

natural form of Env (HIV envelope antigens) under conditions that

elicit tightly binding Ab. GeoVax studie
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. Biopure Announces 2007 Third Quarter Financial Results
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
7. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Pharmacopeia Announces Third Quarter 2007 Financial Results
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
(Date:12/24/2014)... PHILADELPHIA , Dec. 23, 2014 ... a medical device company focused on skin permeation, ... that Scott W. Hollander has been ... Mr. Hollander has more than 20 years of ... equipment industries, and most recently served as Vice ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... Medical Simulation Corporation (MSC) proudly announces a new agreement ... Medical School and a healthcare leader in patient quality, ... system, Simantha ®, and MSC,s curriculum and training ... and patient safety goals over the next three years. ...
... Pfizer (NYSE: PFE ) today ... Inc., a privately held drug discovery and clinical development ... a wholly owned subsidiary of Pfizer Inc.   ... Pfizer Inc: Working together for a healthier ...
Cached Medicine Technology:Medical Simulation Corporation Signs Agreement With a Nationally Ranked Hospital 2
(Date:12/26/2014)... 26, 2014 Plugin and template developers from ... 5 Plugin for Final Cut Pro X. , “TransPack Volume ... tool to pull off an industry professional look” Said Christina ... hands on TransPack Volume 5, a new level of professionalism ... set of over 50 Final Cut Pro X transitions featuring ...
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... says more than 2 dozen contain dangerous ingredients not ... -- The U.S. Food and Drug Administration warned consumers ... for weight loss because they contain undeclared ingredients that ... sold in some retail stores and on the Internet ...
... developed a new generation of microscopic particles for ... nanoparticle platforms that may be readily adapted for ... , According to the investigators at Memorial ... particles are biologically safe, stable, and small enough ...
... UPTON, NY Scientists at the U.S. Department of ... structure of a third subtype of botulinum neurotoxin ... the disease botulism, and is also used in cosmetic ... a hyperactive bladder. The detailed structure, published online December ...
... you,ve been offered the perfect job. The not-so-good news ... the disabled, people with diseases like HIV, or those who ... room, undergoing a medical exam to qualify for a job ... Aviv University brings excellent news. , Medical exams are often ...
... are less sensitive to thermal (hot and cold) sensations later ... London). The study, published in the journal Pain , ... in early development may alter how children respond to painful ... 43 eleven-year-old children born at less than 26 weeks of ...
... switch ,on, in those with lupus, rheumatoid arthritis , , ... potential autoimmune disease-causing cells, but these cells stay in ... cells that attack the body cause autoimmune diseases such ... cells in healthy adults are true precursors of the ...
Cached Medicine News:Health News:FDA Warns About Weight Loss Products 2Health News:FDA Warns About Weight Loss Products 3Health News:Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting 2Health News:Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting 3Health News:Scientists reveal structure of new botulism nerve toxin subtype 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 3Health News:A simple questionnaire to replace a doctor's exam 2Health News:Premature babies have altered sensory responses in later life 2
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
... Double Antibody Estradiol,is an 125I ... use in the quantitative,measurement of ... of precocious puberty in girls,and ... the,differential diagnosis of amenorrhea. It ...
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... most potent, naturally secreted estrogen and is ... [1]. In the ovary, estradiol is produced ... less potent estrogen derived from androstenedione. Estrone ... tissues. In men, small amounts of estradiol ...
Medicine Products: